NCT06050941View on ClinicalTrials.gov

Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

April 2, 2024

Primary Completion Date

April 2, 2026

Study Completion Date

April 2, 2027

Conditions

Acute Myeloid LeukemiaMyelodysplastic Syndromes

Interventions

DRUG

idarubicin

Idarubicin 6mg/m2 d5-7

DRUG

Cytarabine

Cytarabine 60mg/m2 d5-9

All Listed Sponsors

lead

First Affiliated Hospital of Zhejiang University

OTHER